

Evaluation of ER α , PR and ER β isoforms in neoadjuvant treated breast cancer

MARTIN WURSTER^{1*}, ALEXANDRA RUOFF^{1*}, CHRISTOPH MEISNER³, HARALD SEEGER¹,
ULRICH VOGEL², INGOLF JUHASZ-BÖSS⁴, ERICH SOLOMAYER⁴, DIETHELM WALLWIENER¹,
TANJA FEHM¹ and HANS NEUBAUER¹

¹Department of Obstetrics and Gynecology, and ²Institute of Pathology, University of Tuebingen, D-72076 Tuebingen;

³Department of Medical Biometry, University of Tuebingen, D-72070 Tuebingen; ⁴Department of Gynecology, Obstetrics and Reproductive Medicine, University of Saarland, D-66421 Homburg, Germany

Received December 7, 2009; Accepted February 22, 2010

DOI: 10.3892/or_00000904

Abstract. The actual predictive value of oestrogen receptor (ER) β for treatment decisions in breast cancer is still unclear. Retrospective studies using preoperative systemic therapy (PST) revealed that chemotherapy but also endocrine therapy can lead to alterations in expression levels of ER α and progesterone receptor (PR). The main purpose of this study was to compare ER β expression levels before and after neoadjuvant chemotherapy or endocrine therapy and to explore a possible predictive value of ER β . Matching 'baseline' biopsies and post-therapy surgical specimens of 69 breast cancer patients treated with neoadjuvant anthracycline- or taxane-based chemotherapy or with aromatase inhibitors were analyzed for expression levels of ER α , PR, total ER β (ER β t), ER β 1, ER β 2 and the proliferation-related antigen Ki-67 using immunohistochemistry. A marked expression of ER β t significantly correlates with low proliferation rates after PST ($p=0.0013$) and with response to it. Further most tumours decreased ER β 1 expression with PST. A marked ER β 2 expression was observed predominantly in responders and significantly decreased during chemotherapy ($p=0.047$). Results on ER α and PR corroborate findings of previous studies. Our data demonstrate that changes of ER β expression occur during PST and that total ER β expression and ER β 2 may have a predictive value for PST.

Introduction

The oestrogen receptor β (ER β) and its isoforms are promising new potential biological markers in breast cancer. It is likely

that ER β can be used as a predictive marker for response to endocrine therapy or as a therapeutic target in the future. Therapy decisions in breast cancer are to a great extent guided by hormone receptor expressions. So far only estrogen receptor α (ER α) and progesterone receptor (PR) are routinely evaluated in breast cancer patients (1). For several years now research is focusing on the potential prognostic and predictive role of ER β and its variant isoforms in breast cancer. Most of these isoforms are splice variants or exon deletion isoforms (2,3). The so far best characterized isoforms are ER β 1, the wild-type form, and ER β 2 (also known as ER β c α) which is a splice variant of ER β 1 (4,5; reviewed in refs. 6 and 7). Data on the role of ER β are often conflicting due to the circumstance that the different ER β isoforms most likely have different biological functions or clinical values (3,5-10). However, there seems to be a consensus on a role of ER β as a tumour suppressor (reviewed in refs. 11 and 12). Another challenge in the process of establishing ER β and its isoforms as new biological markers in routine diagnostics remains the development of a standardized and quality controlled scoring system for immunohistochemical detection of ER β and its isoforms (1,13,14).

Neoadjuvant or preoperative systemic therapy (PST) provides an excellent model for researchers to evaluate the expression of biological markers such as hormone receptors before and after therapy in order to gain a deeper understanding of tumour biology. Several research groups observed significant changes in expression levels of tumour parameters like ER α , PR or Her-2 during PST (15-23). Therefore, it is strongly recommended that hormone receptor expression and other biological markers should be re-evaluated after PST in order to make sure that post-surgery treatment is tailored adequately. ER α and PR are established predictive markers to select patients for an endocrine therapy in breast cancer. However, some research groups also found that ER α and PR are likely to have a predictive value for chemotherapy as well, most of them stating a correlation of ER α and PR negativity with chemotherapy response (18,24-27). Rody and colleagues observed in a neoadjuvant study that Her-2 seems to be highly predictive for chemotherapy outcome (24). Concerning ER β Miller and colleagues focused on ER β expression with

Correspondence to: Dr Hans Neubauer, Department of Obstetrics and Gynecology, University of Tuebingen, Calwerstr. 7/6, Baden-Wuerttemberg, D-72076 Tuebingen, Germany
E-mail: hans.neubauer@med.uni-tuebingen.de

*Contributed equally

Key words: estrogen receptor β , isoforms, neoadjuvant therapy, breast cancer

Table I. Treatment applied.

PST	Regimen	Dose (mg/m ²)
Anthracycline-based	A/E+C	60/90+600
Taxane-based	A/E+T	50/90+75
	E+C+T	90+500+75
Aromatase inhibitor	Letrozole	2.5 mg
	Exemestane	25 mg

A, adriamycin; C, cyclophosphamide; E, epirubicin; T, docetaxel.

neoadjuvant tamoxifen therapy and observed a decrease of ER β 1 (28). Possible effects of aromatase inhibitors or chemotherapy on ER β or a possible predictive value of ER β for cytotoxic drugs remain to be investigated. Advancing our knowledge about interactions of different cytoreductive drugs with ER β will lead to a better understanding about the relevance of ER β and its isoforms for therapy decisions in breast cancer.

Based on this background the purpose of this study was to assess possible effects of different PST regimens on ER α and PR but also on ER β 1, ER β 2 and total ER β (ER β t) (including all isoforms) expression levels. We also focused on the question whether ER β t, ER β 1 or ER β 2 may have any predictive relevance for these therapies. Hormone receptor proteins were detected semi-quantitatively using immunohistochemistry. We compared expression levels before and after anthracycline-based or taxane-based neoadjuvant chemotherapy or neoadjuvant endocrine therapy with the aromatase inhibitors letrozole and exemestane.

Patients and methods

Tissue samples from 69 breast cancer patients with non-metastatic invasive primary breast carcinoma (cT1-4, Mo) have been included into the study. They have undergone PST at the Department of Gynaecology and Obstetrics, University Hospital, Tuebingen, Germany, from January 1999 until January 2003. All patients provided diagnostic core biopsy of the breast tumour to confirm invasive cancer before starting treatment. All specimens were obtained after written informed consent and collected using a protocol approved by the local ethics committee (AZ 266/98).

Chemotherapy schedules and surgery. Patients received 4-6 cycles of either an anthracycline (n=17) or taxane (n=30) based therapy administered at 21-day intervals or neoadjuvant endocrine treatment with letrozole or exemestane (n=22) daily for 6 months (Table I). Surgery was performed ~1 month after the final cycle of chemotherapy. Patients who had no remaining invasive cancer in the breast and who were lymph node negative were considered to have a pathologically complete response (CR).

Assessment of response. Response to PST was evaluated pathologically by classifying the regressive changes using a semi-

Table II. Classification of hormone receptor expression.

IRS-score	Classification I	Classification II
0	0 = negative	0 = negative
1-3	1 = weakly positive	1 = weakly positive
4-7	2 = intermediately positive	1 = weakly positive
8-12	3 = strongly positive	2 = strongly positive

quantitative scoring system from 0 to 4 [0, no effect; 1, resorption and tumour sclerosis; 2, minimal residual invasive tumour (<0.5 cm); 3, residual non-invasive tumour only; 4, no tumour detectable] according to the tumour regression grading described by Sinn *et al* (29). A consultant pathologist (U.V.) blinded to clinical outcome reviewed all paired biopsy and surgical specimens. Labelled sections were investigated in a blinded fashion by M.W. and U.V. who did not know the kind of treatment used. All sections were digitally documented and labelling was semi-quantitatively scored. Labelling for Ki-67 was scored in a different way: only the percentage of positive tumour cells was scored. If >10% of the cells were labelled the score was positive.

Labelling of hormone receptors was scored according to the 'immune reactive score' (IRS) established by Remmele and Stegner (30). This score calculates the percentage of positive nuclei (0, 0%; 1, <10%; 2, 10-50%; 3, 50-80% and 4, >80% of positive cells) and the staining intensity (0, negative; 1, weak; 2, moderate; and 3, strong staining). The IRS is calculated by multiplying both values providing scores between 0 and 12.

Tumour samples were classified according to their receptor expression in two ways (Table II): classification I was used to investigate co-expressions, proliferation and changes in receptor expression; classification II was applied to investigate receptor expression and response to therapy.

Immunohistochemistry. The immunohistochemical (IHC) analysis was performed on tissue microarrays (TMA) produced from cut core biopsies and surgical resection specimens. Tissue samples have been fixed in 4.5% buffered formalin (pH 7.0) and embedded in paraffin. IHC was performed on TMA sections (4 μ m) mounted onto Superfrost glass slides. In total four TMAs have been produced with 150 cores each. For IHC CytoChem-Plus HRP kit, Broad Spectrum (Zytomed, Berlin, Germany) was used. Briefly, before incubation with primary antibody unspecific binding was blocked with Blocking Solution-SuperBlock for 5 min. After washing once primary antibodies were incubated in appropriate dilutions for optimized incubation times (Table III). Primary antibodies were diluted in Antibody Diluent (Dako, Hamburg, Germany) and applied according to the manufacturer's instruction. DAB (3,3'-diaminobenzidine) was used as chromogen. Finally, the slides were counterstained with Mayer's haematoxylin for 10 sec and mounted for examination.

For each antibody a positive tissue sample was used as positive control. For negative control the same section was incubated without the primary antibody. Reactions were performed in a humidified chamber. Counter staining was done



Antibody	Species	Dilution	Supplier	Refs.
ERβt	Mouse monoclonal (14C8; specific for as 1-153 of human ERβ)	1:1000	GeneTex, Inc., San Antonio, TX, USA	(13,46)
ERβ1	Mouse monoclonal (PPG5/10, specific for c-terminal peptide of ERβ1)	1:1000	Serotec, Oxford, UK	(47,48)
ERβ2	Mouse monoclonal (57/3, specific for c-terminal peptide of ERβ2)	1:500	Acris, Hidden-hausen, Germany	(49,50)
ERα	Rabbit monoclonal (SP1, specific for c-terminal peptide of ERα)	1:200	DCS, Hamburg, Germany	(51)
PR	Rabbit monoclonal (SP2, specific for as 412-526 of human PR)	1:200	DCS	(52-54)
Ki-67	Mouse monoclonal (Mib-1)	1:200	DakoCytomation, Hamburg, Germany	(55-57)
CK18	Mouse monoclonal (DC 10)	1:2000	Dako	(58)

with Papanicolaous solution 1a (Harris' Hematoxylin) for 30 sec.

Statistical analysis. To find correlations between two parameters χ^2 test was performed. P-values <0.05 were regarded as significant. For analysis of receptor co expression multi-variate correlation was performed and the correlation coefficient was calculated according to Spearman, since classes were not equally distributed.

Results

Clinical characteristics and response to treatment. Sixty-nine breast cancer patients were investigated in our study. Clinical data are presented in Table IV. After PST response to treatment (partial remission, complete remission) was reached in 49.3% of the cases. 50.7% were non-responders. Positive lymph nodes were seen in 65.2% of the patients. The predominant histological tumour type was invasive ductal carcinoma (63.8%) followed by invasive lobular carcinoma in 20.3% of the cases. The majority of the patients was post-menopausal.

ERα. ERα was detectable only in nuclei of epithelial cells (Fig. 1). Most of the tumours (79.7%) were ERα positive. A correlation of ERα negativity and proliferation could be observed ($\chi^2=4.2$; $p=0.04$). After PST this correlation was more pronounced and significant ($\chi^2=17.5$; $p<0.0001$). During PST ERα expression decreased in 27.5% of the tumours and stayed unchanged in 68.1%. Furthermore, ERα expression was observed to decrease more often in responders to PST (40.7%) than in non-responders (10%).

PR. Like ERα PR was detectable only in nuclei of epithelial cells. Most of the tumours were classified as PR positive. We observed a distinct decrease of PR during PST in all 3 therapy groups (66.7%) but most prominent in the endocrine therapy group (77.3%). Such a decrease could be made out more often in pre-menopausal than in post-menopausal women (data not shown).

Table IV. Basic patient characteristics after primary systemic therapy.

Total	N (%)
	69 (100)
Menopausal status	
Pre	12 (17.4)
Peri	8 (11.6)
Post	49 (71.0)
Tumour size	
ypT1	17 (24.6)
ypT2	33 (47.8)
ypT3	12 (17.4)
ypT4	7 (10.1)
Nodal status	
yN negative	24 (34.8)
yN positive	45 (65.2)
Grading	
I	3 (4.3)
II	47 (68.1)
III	19 (27.5)
Histology	
Ductal	44 (63.8)
Lobular	14 (20.3)
Ductulo-lobular	8 (11.6)
Others	3 (4.3)
Primary systemic therapy	
Anthracycline-based	17 (24.6)
Taxane-based	30 (43.5)
Aromatase inhibitors	22 (31.9)
Therapy response	
Responders	34 (49.3)
Non-responders	35 (50.7)

ypT, post-chemotherapy pathologic T classification; yN, post-chemotherapy pathologic N classification.




Figure 1. Immunohistochemistry for hormone receptors. Depicted are typical staining obtained for (A) ER α expression is detected only in nuclei of epithelial cells; (B) ER β isoforms, nuclear expression; (C) ER β isoforms, nuclear and weak cytoplasmic staining; (D) ER β isoforms in fibroblasts (arrows); (E) ER β isoforms in inflammatory cells; (F) ER β isoforms in breast cancer cells (arrows) and fibroblasts (arrowheads). Magnifications: (A, D and F), x40; (B and C), x20; (E), x10.

Total ER β expression (ER β t, including all isoforms). ER β t could be detected in nuclei as well as in the cytoplasm of epithelial cells, fibroblasts and inflammatory cells (Fig. 1). The majority of the tumours (73.9%) were strongly positive for ER β t. Tumours with a strong expression of ER β t were significantly more often classified as non-proliferating after chemotherapy than tumours which were only weakly positive for ER β t ($\chi^2=10.4$; $p=0.0013$). Furthermore a strong ER β t expression was tendentially more often observed in responders (81.4%) to chemotherapy than in non-responders (50%).

ER β 1. Like ER β t, ER β 1 could be detected in nuclei as well as in the cytoplasm of epithelial cells, fibroblasts and inflammatory cells (Fig. 1). Most of the tumour specimens (62.3%) were classified as strongly positive for ER β 1. We observed a decrease of ER β 1 during chemotherapy in 55.3% of cases.

ER β 2. Like ER β 1 and ER β t, ER β 2 was detectable in nuclei and in the cytoplasm of mammary epithelial cells, fibroblasts and inflammatory cells (Fig. 1). The majority of the tumours (47.8%) were strongly positive for ER β 2.

Responders to chemotherapy often showed a stronger ER β 2 expression than non-responders (Table V). This could be observed predominantly in the taxane-group. We further

observed that responders to chemotherapy decreased ER β 2 significantly more often than non-responders ($\chi^2=6.1$; $p=0.047$) particularly in the taxane-group (Table V).

Hormone receptor co expressions. ER α and PR were significantly co-expressed in our tumour specimens ($r=0.58$; $p<0.0001$), but neither ER α nor PR expression correlated with expression levels of ER β t, ER β 1 or ER β 2 (data not shown). Since ER β t includes all ER β isoforms we found a significant co expression of ER β t with ER β 1 ($r=0.4$; $p=0.0008$) and also with ER β 2 ($r=0.38$; $p=0.0013$) as expected. There was also a significant correlation of ER β 1 and ER β 2 ($r=0.35$; $p=0.0031$) detectable.

Discussion

ER β isoforms vary and correlate with chemotherapy response. Although the number of samples investigated is small this neoadjuvant immunohistochemical study provides evidence that oestrogen receptor β expression can change during PST and that especially a change in ER β 2 expression significantly correlates with chemotherapy response. Our data on ER α and PR mainly substantiate findings of other research groups.

A. ER $\beta 2$ expression and therapy response.^a

	ER $\beta 2$					
	Anthracycline + Taxane			Taxane		
	Negative (%)	Weak (%)	Strong (%)	Negative (%)	Weak (%)	Strong (%)
Responders	0	13 (48.1)	14 (51.9)	0	9 (60)	6 (40)
Non-responders	0	14 (70)	6 (30)	0	12 (80)	3 (20)

B. Change in immunohistochemical score with PST.

	ERβ2						P-value
	Anthracycline + Taxane			Taxane			
	Decrease (%)	No change (%)	Increase (%)	Decrease (%)	No change (%)	Increase (%)	
Responders	13 (48.1)	9 (33.3)	5 (18.5)	7 (46.7)	5 (33.3)	3 (20)	χ²=6.1; P=0.047
Non-responders	3 (15)	12 (60)	5 (25)	1 (6.7)	9 (60)	5 (33.3)	

^aNo significant differences between responding and non-responding tumours.

Variations of oestrogen receptor α and progesterone receptor during neoadjuvant therapy. A decrease of ER α expression in responders to PST has already been described (18). Our data confirm these findings and support the hypothesis that chemotherapy can induce significant variations in ER α expression. We further observed a down-regulation of PR expression levels in all therapy groups. A decrease of PR during neoadjuvant therapy with aromatase inhibitors but also during an anthracycline-based chemotherapy is also known from the literature (15,16,21-23,31). Therefore, a re-evaluation of ER α and PR status after PST is strongly recommended in order to optimize individual therapy decisions based on the actual receptor expression. In the endocrine therapy group we found a decrease of PR predominantly in premenopausal women. This is most likely due to the fact that endocrine therapy induces menopause resulting in a down-regulation of PR.

Specific detection of ER β isoforms. In the process of establishing ER β as a prognostic or predictive parameter, in order to guide individual decision making for the treatment of breast cancer, it is necessary to develop a standardized scoring system for a specific detection of the different isoforms (1,5,13,14). In this study we established an immunohistochemical staining approach and scoring system which allows detecting expression levels of ER $\beta 1$ and ER $\beta 2$ specifically. The detection of ER β and its isoforms not only in nuclei of mammary epithelial cells but also in the nuclei and cytoplasm of endothelial cells, fibroblasts and inflammatory cells is already known from the literature (6,32,33). However, we evaluated and compared ER β expression only in mammary epithelial cells in order to gain as valid data as possible on ER β in carcinoma cells.

ER $\beta 1$ might act as a predictive marker for chemotherapy. There is a solidifying consensus that ER β acts as a tumour suppressor in breast cancer and has a protective role against the development of a malignancy (reviewed in ref. 11). Moreover, Lazennec and colleagues stress an antiproliferative effect of ER β on breast cancer cells (34). Our data demonstrate that a strong expression of ER $\beta 1$ significantly correlates with low proliferation rates after chemotherapy. This corroborates the assumption of an antiproliferative effect of ER $\beta 1$. We further observed that responders to chemotherapy tend to be more often strongly positive for ER $\beta 1$ than non-responders. These findings suggest that ER $\beta 1$ might act as a positive predictive parameter for chemotherapy. Since the phenomenon was most pronounced in the anthracycline group it might be speculated that ER $\beta 1$ has a predictive value especially for an anthracycline-based chemotherapy.

ER $\beta 1$ decreases during neoadjuvant chemotherapy. Our data demonstrate that ER $\beta 1$ expression decreases in the tumour cells during primary systemic chemotherapy. Since the different chemotherapy groups show a similar decrease in ER $\beta 1$ we assume that the down-regulation might not be due to specific effects or signal transductions of the drugs on the tumour cells. A possible explanation for the unspecific decrease of ER $\beta 1$ might be alterations in the tumour extracellular matrix (ECM). However, this hypothesis needs to be confirmed. A lot of studies revealed that changes in the composition of the ECM or in cell-matrix-interaction processes frequently occur in breast cancer which also leads to alterations in expression levels of tumour relevant proteins such as hormone receptors (35-38). We recently observed a decrease of ER $\beta 1$ in MDA-MB-231 breast cancer cells by a laminin-rich basement membrane matrix (39).

ER β 2 might have a predictive value for chemotherapy. Expression of ER β 2 is suggested to exert an antiproliferative or tumour suppressive effect (40,41). Furthermore, we find that responder to chemotherapy more often show a strong expression of ER β 2 compared to non-responder, which highly suggests that ER β 2 might have a predictive value for chemotherapy, especially for a taxane-based chemotherapy since the effect could be observed most prominent in the taxane-group of our study. Taxanes have many biological effects which appear to be related to its ability to promote an assembly of microtubules stabilizing them against depolymerising agents (19,42). However, taxanes are also known to exert several effects which are mediated by other mechanisms (19,43-45). It might be speculated that tumour cells strongly positive for ER β 2 are more sensitive to taxane-mediated effects. Based on this hypothesis ER β 2-positive tumour cells are primarily annihilated by chemotherapy. Remaining tumour tissue after chemotherapy therefore consists of cells with weak ER β 2 expression levels, or cells mainly ER β 2 negative. This might explain why responders to taxanes in our study show significantly more often a marked decrease of ER β 2 expression (or a shift from ER β 2 positivity to negativity) after therapy than non-responders. Taken together, we conclude from our data that ER β 2 may have a predictive value for a taxane-based chemotherapy, however, the underlying molecular biological reason remains to be investigated.

In conclusion, this study reveals that PST influences ER β expression in breast cancer and that tumour proliferation and chemotherapy response are correlated with ER β expression. ER β t and ER β 2 seem to have a predictive value for chemotherapy.

Acknowledgements

The authors are grateful to B. Kootz for support in immunohistochemistry.

References

- Skliris GP, Leygue E, Watson PH and Murphy LC: Oestrogen receptor alpha negative breast cancer patients: oestrogen receptor beta as a therapeutic target. *J Steroid Biochem Mol Biol* 109: 1-10, 2008.
- Poola I, Abraham J and Baldwin K: Identification of ten exon deleted ERbeta mRNAs in human ovary, breast, uterus and bone tissues: alternate splicing pattern of oestrogen receptor beta mRNA is distinct from that of oestrogen receptor alpha. *FEBS Lett* 516: 133-138, 2002.
- Treeck O, Pfeiler G, Horn F, Federhofer B, Houlihan H, Vollmer A and Ortmann O: Novel estrogen receptor beta transcript variants identified in human breast cancer cells affect cell growth and apoptosis of COS-1 cells. *Mol Cell Endocrinol* 264: 50-60, 2007.
- Ogawa S, Inoue S, Watanabe T, Orimo A, Hosoi T, Ouchi Y and Muramatsu M: Molecular cloning and characterization of human estrogen receptor betacx: a potential inhibitor of estrogen action in human. *Nucleic Acids Res* 26: 3505-3512, 1998.
- Moore JT, McKee DD, Slentz-Kesler K, Moore LB, Jones SA, Horne EL, Su JL, Kliever SA, Lehmann JM and Willson TM: Cloning and characterization of human oestrogen receptor beta isoforms. *Biochem Biophys Res Commun* 247: 75-78, 1998.
- Speirs V, Carder PJ, Lane S, Dodwell D, Lansdown MR and Hanby AM: Oestrogen receptor beta: what it means for patients with breast cancer. *Lancet Oncol* 5: 174-181, 2004.
- Mitter D, Ortmann O and Treeck O: Oestrogen receptor beta isoforms - functions and clinical relevance in breast cancer. *Zentralbl Gynakol* 127: 228-234, 2005.
- Mandusic V, Nikolic-Vukosavljevic D, Tanic N, Kanjer K, Neskovic-Konstantinovic Z, Celeketic D and Dimitrijevic B: Expression of oestrogen receptor beta wt isoform (ERbeta1) and ERbetaDelta5 splice variant mRNAs in sporadic breast cancer. *J Cancer Res Clin Oncol* 133: 571-579, 2007.
- Leung YK, Mak P, Hassan S and Ho SM: Oestrogen receptor (ER)-beta isoforms: a key to understanding ER-beta signaling. *Proc Natl Acad Sci USA* 103: 13162-13167, 2006.
- Lewandowski S, Kalita K and Kaczmarek L: Oestrogen receptor beta. Potential functional significance of a variety of mRNA isoforms. *FEBS Lett* 524: 1-5, 2002.
- Zhao C, Dahlman-Wright K and Gustafsson JA: Oestrogen receptor beta: an overview and update. *Nucl Recept Signal* 6: E003, 2008.
- Honma N, Saji S, Kurabayashi R, Aida J, Arai T, Horii R, Akiyama F, Iwase T, Harada N, Younes M, Toi M, Takubo K and Sakamoto G: Oestrogen receptor-beta1 but not oestrogen receptor-beta2 is of prognostic value in apocrine carcinoma of the breast. *APMIS* 116: 923-930, 2008.
- Skliris GP, Parkes AT, Limer JL, Burdall SE, Carder PJ and Speirs V: Evaluation of seven oestrogen receptor beta antibodies for immunohistochemistry, Western blotting and flow cytometry in human breast tissue. *J Pathol* 197: 155-162, 2002.
- Esslimani-Sahla M, Kramar A, Simony-Lafontaine J, Warner M, Gustafsson JA and Rochefort H: Increased oestrogen receptor betacx expression during mammary carcinogenesis. *Clin Cancer Res* 11: 3170-3174, 2005.
- Taucher S, Rudas M, Gnant M, Thomanek K, Dubsy P, Roka S, Bachleitner T, Kandioler D, Wenzel C, Steger G, Mittlböck M and Jakesz R: Sequential steroid hormone receptor measurements in primary breast cancer with and without intervening primary chemotherapy. *Endocr Relat Cancer* 10: 91-98, 2003.
- Dowsett M, Ebbs SR, Dixon JM, Skene A, Griffith C, Boeddinghaus I, Salter J, Detre S, Hills M, Ashley S, Francis S, Walsh G and Smith IE: Biomarker changes during neoadjuvant anastrozole, tamoxifen or the combination: influence of hormonal status and HER-2 in breast cancer - a study from the IMPACT trialists. *J Clin Oncol* 23: 2477-2492, 2005.
- Neubauer H, Gall C, Vogel U, Hornung R, Wallwiener D, Solomayer E and Fehm T: Changes in tumour biological markers during primary systemic chemotherapy (PST). *Anticancer Res* 28: 1797-1804, 2008.
- Frassoldati A, Adami F, Banzi C, Criscuolo M, Piccinini L and Silingardi V: Changes of biological features in breast cancer cells determined by primary chemotherapy. *Breast Cancer Res Treat* 44: 185-192, 1997.
- Martin MB, Angeloni SV, Garcia-Morales P, Sholler PF, Castro-Galache MD, Ferragut JA and Saceda M: Regulation of oestrogen receptor-alpha expression in MCF-7 cells by taxol. *J Endocrinol* 180: 487-496, 2004.
- Burcombe RJ, Makris A, Richman PI, Daley FM, Noble S, Pittam M, Wright D, Allen SA, Dove J and Wilson GD: Evaluation of ER, PR, HER-2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer. *Br J Cancer* 92: 147-155, 2005.
- Miller WR, Dixon JM, Macfarlane L, Cameron D and Anderson TJ: Pathological features of breast cancer response following neoadjuvant treatment with either letrozole or tamoxifen. *Eur J Cancer* 39: 462-468, 2003.
- Miller WR, White S, Dixon JM, Murray J, Renshaw L and Anderson TJ: Proliferation, steroid receptors and clinical/pathological response in breast cancer treated with letrozole. *Br J Cancer* 94: 1051-1056, 2006.
- Rody A, Karn T, Gätje R, Kourtis K, Minckwitz G, Loibl S, Munnes M, Ruckhäberle E, Holtrich U, Kaufmann M and Ahr A: Gene expression profiles of breast cancer obtained from core cut biopsies before neoadjuvant docetaxel, adriamycin and cyclophosphamide chemotherapy correlate with routine prognostic markers and could be used to identify predictive signatures. *Zentralbl Gynäkol* 128: 76-81, 2006.
- Rody A, Karn T, Gätje R, Ahr A, Solbach C, Kourtis K, Munnes M, Loibl S, Kissler S, Ruckhäberle E, Holtrich U, von Minckwitz G and Kaufmann M: Gene expression profiling of breast cancer patients treated with docetaxel, doxorubicin, and cyclophosphamide within the GEPARTRIO trial: HER-2, but not topoisomerase II alpha and microtubule-associated protein tau, is highly predictive of tumour response. *Breast* 16: 86-93, 2007.



SPANDIDOS³, Yang DQ and Xie F: Biological markers as predictive of response to neoadjuvant taxanes and anthracycline chemotherapy in breast carcinoma. *Chin Med J (Engl)* 121: 387-391, 2008.

26. Wang S, Yang H, Tong F, Zhang J, Yang D, Liu H, Cao Y, Liu P, Zhou P, Cheng L, Liu M and Guo J: Response to neoadjuvant therapy and disease-free survival in patients with triple-negative breast cancer. *Gan To Kagaku Ryoho* 36: 255-258, 2009.
27. Liedtke C, Mazouni C, Hess KR, André F, Tordai A, Mejia JA, Symmans WF, Gonzalez-Angulo AM, Hennessy B, Green M, Cristofanilli M, Hortobagyi GN and Pusztai L: Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. *J Clin Oncol* 26: 1275-1281, 2008.
28. Miller WR, Anderson TJ, Dixon JM and Saunders PT: Oestrogen receptor beta and neoadjuvant therapy with tamoxifen: prediction of response and effects of treatment. *Br J Cancer* 94: 1333-1338, 2006.
29. Sinn HP, Schmid H, Junkermann H, Huober J, Leppien G, Kaufmann M, Bastert G and Otto HF: Histologic regression of breast cancer after primary (neoadjuvant) chemotherapy. *Geburtshilfe Frauenheilkd* 54: 552-558, 1994.
30. Remmele W and Stegner HE: Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical oestrogen receptor detection (ER-ICA) in breast cancer tissue. *Pathologe* 8: 138-140, 1987.
31. Anderson TJ, Dixon JM, Stuart M, Sahmoud T and Miller WR: Effect of neoadjuvant treatment with anastrozole on tumour histology in post-menopausal women with large operable breast cancer. *Br J Cancer* 87: 334-338, 2002.
32. Skliris GP, Carder PJ, Lansdown MR and Speirs V: Immunohistochemical detection of ERbeta in breast cancer: towards more detailed receptor profiling? *Br J Cancer* 84: 1095-1098, 2001.
33. Shaaban AM, Green AR, Karthik S, Alizadeh Y, Hughes TA, Harkins L, Ellis IO, Robertson JF, Paish EC, Saunders PT, Groome NP and Speirs V: Nuclear and cytoplasmic expression of ERbeta1, ERbeta2 and ERbeta5 identifies distinct prognostic outcome for breast cancer patients. *Clin Cancer Res* 14: 5228-5235, 2008.
34. Lazennec G, Bresson D, Lucas A, Chauveau C and Vignon F: ER beta inhibits proliferation and invasion of breast cancer cells. *Endocrinology* 142: 4120-4130, 2001.
35. Kass L, Erler JT, Dembo M and Weaver VM: Mammary epithelial cell: influence of extracellular matrix composition and organization during development and tumorigenesis. *Int J Biochem Cell Biol* 39: 1987-1994, 2007.
36. Nelson CM and Bissell MJ: Of extracellular matrix, scaffolds and signaling: tissue architecture regulates development, homeostasis and cancer. *Annu Rev Cell Dev Biol* 22: 287-309, 2006.
37. Bissell MJ, Kenny PA and Radisky DC: Microenvironmental regulators of tissue structure and function also regulate tumour induction and progression: the role of extracellular matrix and its degrading enzymes. *Cold Spring Harb Symp Quant Biol* 70: 343-356, 2005.
38. Berrier AL and Yamada KM: Cell-matrix adhesion. *J Cell Physiol* 213: 565-573, 2007.
39. Neubauer H, Ruoff A, Paessler N, Solomayer E, Wallwiener D and Fehm T: A laminin-rich basement membrane matrix influences oestrogen receptor beta expression and morphology of MDA-MB-231 breast cancer cells. *Oncol Rep* 21: 475-481, 2009.
40. Omoto Y, Eguchi H, Yamamoto-Yamaguchi Y and Hayashi S: Oestrogen receptor (ER) beta1 and ERbeta2/beta2 inhibit ERalpha function differently in breast cancer cell line MCF7. *Oncogene* 22: 5011-5020, 2003.
41. Sugiura H, Toyama T, Hara Y, Zhang Z, Kobayashi S, Fujii Y, Iwase H and Yamashita H: Expression of oestrogen receptor beta wild-type and its variant ERbeta2/beta2 is correlated with better prognosis in breast cancer. *Jpn J Clin Oncol* 37: 820-828, 2007.
42. Schiff PB and Horwitz SB: Taxol stabilizes microtubules in mouse fibroblast cells. *Proc Natl Acad Sci USA* 77: 1561-1565, 1980.
43. Moos PJ and Fitzpatrick FA: Taxane-mediated gene induction is independent of microtubule stabilization: induction of transcription regulators and enzymes that modulate inflammation and apoptosis. *Proc Natl Acad Sci USA* 95: 3896-3901, 1998.
44. Stein CA: Mechanisms of action of taxanes in prostate cancer. *Semin Oncol* 26: 3-7, 1999.
45. Wang LG, Liu XM, Kreis W and Budman DR: The effect of antimicrotubule agents on signal transduction pathways of apoptosis: a review. *Cancer Chemother Pharmacol* 44: 355-361, 1999.
46. Speirs V, Skliris GP, Burdall SE and Carder PJ: Distinct expression patterns of ER alpha and ER beta in normal human mammary gland. *J Clin Pathol* 55: 371-374, 2002.
47. Saunders PT, Millar MR, Williams K, Macpherson S, Harkiss D, Anderson RA, Orr B, Groome NP, Scobie G and Fraser HM: Differential expression of oestrogen receptor-alpha and -beta and androgen receptor in the ovaries of marmosets and humans. *Biol Reprod* 63: 1098-1105, 2000.
48. Wong NA, Malcomson RD, Jodrell DI, Groome NP, Harrison DJ and Saunders PT: ER beta isoform expression in colorectal carcinoma: an in vivo and in vitro study of clinicopathological and molecular correlates. *J Pathol* 207: 53-60, 2005.
49. Saunders PT, Millar MR, Macpherson S, Irvine DS, Groome NP, Evans LR, Sharpe RM and Scobie GA: ER beta 1 and the ER beta 2 splice variant (ER beta CX/beta 2) are expressed in distinct cell populations in the adult human testes. *J Clin Endocrinol Metab* 87: 2706-2715, 2002.
50. Critchley HO, Henderson TA, Kelly RW, Scobie GS, Evans LR, Groome NP and Saunders PT: Wild-type oestrogen receptor (ER beta 1) and the splice variant (ERbeta CX/beta 2) are expressed within the human endometrium throughout the normal menstrual cycle. *J Clin Endocrinol Metab* 87: 5265-5273, 2002.
51. Fehm T, Krawczyk N, Solomayer EF, Becker-Pergola G, Dürstörzer S, Neubauer H, Seeger H, Staebler A, Wallwiener D and Becker S: ERalpha-status of disseminated tumour cells in bone marrow of primary breast cancer patients. *Breast Cancer Res* 10: R76, 2008.
52. Leake R, Barnes D, Pinder S, Ellis I, Anderson L, Anderson T, Adamson R, Rhodes T, Miller K and Walker R: Immunohistochemical detection of steroid receptors in breast cancer: a working protocol. UK Receptor Group, UK NEQAS, The Scottish Breast Cancer Pathology Group, and The Receptor and Biomarker Study Group of the EORTC. *J Clin Pathol* 53: 634-635, 2000.
53. Mote PA, Johnston JF, Manninen T, Tuohimaa P and Clarke CL: Detection of progesterone receptor forms A and B by immunohistochemical analysis. *J Clin Pathol* 54: 624-630, 2001.
54. Blakeman PJ, Hilton P and Bulmer JN: Oestrogen and progesterone receptor expression in the female lower urinary tract, with reference to oestrogen status. *BJU Int* 86: 32-38, 2000.
55. Scholzen T and Gerdes J: The Ki-67 protein: from the known and the unknown. *J Cell Physiol* 182: 311-322, 2000.
56. Cattoretti G, Becker MH, Key G, Duchrow M, Schlüter C, Galle J and Gerdes J: Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. *J Pathol* 168: 357-363, 1992.
57. Gerdes J, Becker MH, Key G and Cattoretti G: Immunohistochemical detection of tumour growth fraction (Ki-67 antigen) in formalin-fixed and routinely processed tissues. *J Pathol* 168: 85-86, 1992.
58. Lauerova L, Kovarik J, Bartek J, Rejthar A and Vojtesek B: Novel monoclonal antibodies defining epitope of human cytokeratin 18 molecule. *Hybridoma* 7: 495-504, 1988.